Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial. (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s606. https://doi.org/10.25251/yhn4cs07